A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward

Bo Wang^{1*}, Oliver Van Oekelen^{1*}, Tarek H. Mouhieddine², Diane Marie Del Valle¹, Joshua Richter¹, Hearn Jay Cho¹, Shambavi Richard¹, Ajai Chari¹, Sacha Gnjatic¹, Miriam Merad^{1,3}, Sundar Jagannath¹, Samir Parekh¹, Deepu Madduri¹

*Equal contribution

1

3 4

5

6 7 8

9

10

11

12

13

14

43

- 1- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
- Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
- 3- Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

Corresponding author:

- 28 Deepu Madduri, MD
- 29 Tisch Cancer Institute
- 30 Icahn School of Medicine at Mount Sinai
- 31 10 East 102nd Street, 6th Floor, New York, NY 10029
- 32 Phone: 212-241-7873
- 33 deepu.madduri@mountsinai.org

- Journal: Journal of Hematology and Oncology
- 44 Article type: Research Article
- 45 Word count: 3824
- 46 Tables: 4
- 47 Figures: 1 (supplemental)
- 48 References: 40
- 49 Keywords: multiple myeloma, smoldering multiple myeloma, COVID-19, SARS, SARS-Cov-2,
- 50 New York, pandemic

Abstract

Background: The COVID-19 pandemic, caused by SARS-CoV-2 virus, has resulted in over 100,000 deaths in the United States. Our institution has treated over 2,000 COVID-19 patients during the pandemic in New York City. The pandemic directly impacted cancer patients and the organization of cancer care. Mount Sinai Hospital has a large and diverse multiple myeloma (MM) population. Herein, we report the characteristics of COVID-19 infection and serological response in MM patients in a large tertiary care institution in New York.

Methods: We performed a retrospective study on a cohort of 58 patients with a plasma-cell disorder (54 MM, 4 smoldering MM) who developed COVID-19 between March 1, 2020 and April 30, 2020. We report epidemiological, clinical and laboratory characteristics including persistence of viral detection by polymerase chain reaction (PCR) and anti-SARS-CoV-2 antibody testing, treatments initiated, and outcomes.

Results: Of the 58 patients diagnosed with COVID-19, 36 were hospitalized and 22 were managed at home. The median age was 67 years; 52% of patients were male and 63% were non-white. Hypertension (64%), hyperlipidemia (62%), obesity (37%), diabetes mellitus (28%), chronic kidney disease (24%) and lung disease (21%) were the most common comorbidities. In the total cohort, 14 patients (24%) died. Older age (>70 years), male sex, cardiovascular risk, and patients not in complete remission (CR) or stringent CR were significantly (p<0.05) associated with hospitalization. Among hospitalized patients, laboratory findings demonstrated elevation of traditional inflammatory markers (CRP, ferritin, D-dimer) and a significant (p<0.05) association between elevated inflammatory markers, severe hypogammaglobulinemia, non-white race, and mortality. Ninety-six percent (22/23) of patients developed antibodies to SARS-CoV-2 at a median of 32 days after initial diagnosis. Median time to PCR negativity was 43 (range 19-68) days from initial positive PCR.

Conclusions: Drug exposure and MM disease status at the time of contracting COVID-19 had no bearing on mortality. Mounting a severe inflammatory response to SARS-CoV-2 and severe hypogammaglobulinemia were associated with higher mortality. The majority of patients mounted an antibody response to SARS-CoV-2. These findings pave a path to identification of vulnerable MM patients who need early intervention to improve outcome in future outbreaks of COVID-19.

Introduction

The coronavirus disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), represents a world-wide public health crisis. Patient care has been drastically altered, primarily in epidemic, urban areas. As of May 22, 2020, New York City had nearly 200,000 confirmed cases of COVID-19 with over 16,000 deaths and a patient death rate of 21%¹, with cancer patients comprising about 8% of all COVID-19 fatalities in the state of New York². Mount Sinai Hospital, a tertiary care center in New York City, has treated over 2,000 admitted COVID-19 patients thus far. At our cancer center, we actively care for a large and particularly diverse population of over 3000 multiple myeloma (MM) patients. Like many other centers in the region and the world, clinical care at our institution has seen significant changes in an attempt to mitigate the spread of SARS-CoV-2 to vulnerable cancer patients receiving treatment. Balancing the competing risks of treatment delay or alteration versus infection is essential and depends upon understanding the clinical profile of COVID-19 in this vulnerable population.

Limited studies describing the impact of COVID-19 both in the United States³ and abroad⁴⁻⁷ suggest a higher risk of hospitalization and poor outcomes including death in certain subsets of cancer patients. The effect of COVID-19 on patients with MM, the second most common hematological malignancy, is of particularly great concern due to immunosuppression associated with the disease, and at this time remains incompletely understood. MM is a plasma cell malignancy, diagnosed at a median age around 70 years in patients often with multiple comorbidities⁸. MM is associated with both cellular and humoral immune dysfunction and causes a state of generalized immune suppression, leaving patients especially vulnerable to infections^{9,10}.

In contrast to the reported immunosuppressive nature of MM, COVID-19 infection has demonstrated propensity for triggering an uncontrolled immune inflammatory cascade¹¹⁻¹³ that bears resemblance to cytokine release syndrome (CRS) seen in patients treated with chimeric antigen receptor (CAR) T cells and bispecific antibodies^{14,15}. Inflammatory markers and cytokines, including C-reactive protein (CRP), ferritin, interleukin (IL)-6, have been significantly elevated in multiple cohorts of patients infected with COVID-19¹⁶⁻¹⁹.

We aimed to characterize the population of MM patients at our institution who developed COVID-19 in the epicenter of the pandemic in the United States. To address this, we retrospectively analyzed a cohort of 58 MM and smoldering MM (SMM) patients treated at the Mount Sinai Hospital who were diagnosed with COVID-19 between March 1 and April 30, 2020. We have identified several demographic characteristics and comorbidities associated with hospitalization and elevation of certain inflammatory markers associated with increased mortality as described below.

Methods

Study design, inclusion criteria and data collection

The study was designed from a register of patients with SMM and MM in any phase of response, currently receiving treatment or follow-up at the Mount Sinai Hospital. All patients with a confirmed or presumptive diagnosis of COVID-19 between March 1, 2020 and April 30, 2020 were considered potentially relevant. Infection with SARS-CoV-2 was confirmed by Roche Cobas 6800 polymerase chain reaction (PCR) in patients that were treated at the Mount Sinai Hospital. For patients admitted to other hospital systems, inclusion was based on external reporting and follow up testing confirmation. Similarly, outpatients that reported a positive COVID-19 test to our clinic (e.g. over the phone) were included in the analysis, awaiting collection of their formal test results. Anti-SARS-CoV-2 antibody testing was performed using an

anti-IgG assay developed at Mount Sinai Health System Department of Pathology in collaboration with the Icahn School of Medicine at Mount Sinai Department of Microbiology under a Food and Drug Administration (FDA) Emergency Use Authorization. We reviewed clinical charts, nursing records, laboratory findings and radiological images for patients and obtained demographic data from the electronic medical records. Plasma levels of selected inflammatory cytokines, including IL-1β, IL-6, IL-8 and tumor necrosis factor-α (TNF-α), were assessed using the ELLA rapid detection enzyme-linked immunosorbent assay (ELISA) microfluidics platform and made available through the Mount Sinai data warehouse for hospitalized patients. Treatment response criteria were used as defined by the International Myeloma Working Group (IMWG)^{20,21}. This retrospective study was approved by the institutional review board (IRB) of the Mount Sinai Hospital and is in compliance with the Declaration of Helsinki and International Conference on Harmonization Guidelines for Good Clinical Practice (IRB: GCO#: 11-1433).

Statistical analysis

Continuous variables are presented as a median and interquartile range (IQR). Categorical variables are shown as percentage and absolute number of patients. Wherever two outcome groups are compared, Fisher's exact test was used to determine significance and odds ratios (ORs) were reported for categorical variables and Mann-Whitney U test was used to determine significance for continuous variables. A two-sided alpha < 0.05 was considered statistically significant. All statistical analyses were done using R (version 3.6.1).

Data availability

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

The datasets analyzed during the current study are not publicly available due to United States Federal Health Insurance Portability and Accountability Act (HIPAA) compliance, but a deidentified dataset may be available from the corresponding author on reasonable request. Results **Baseline characteristics** Our cohort of 58 patients encompassed 52% males and had a median age of 67 years (IQR: 12.5 years), with 17% of patients older than 75 years (Table 1). The median body mass index (BMI) was 27.6 kg/m² (with 37% of patients with a BMI > 30 kg/m²). The majority of patients reported being non-white (63%), with 13 (23%) patients of African American and 9 (16%) of Hispanic origin. The most common comorbidities were hypertension (64%), hyperlipidemia (62%), previous or active smoking (37%), diabetes mellitus type 2 (28%), chronic kidney disease (CKD, estimated glomerular filtration rate (eGFR) <60 mL/min) (24%) and lung disease (21%), including asthma or chronic obstructive lung disease (COPD). Thirty-two patients (55%) had a high-risk cardiovascular profile (defined as having ≥2 of the conditions: hypertension, hyperlipidemia and diabetes) and 13 (22%) had coronary artery disease (CAD) and/or cerebrovascular disease. Seven (12%) patients had congestive heart failure. Twelve (21%) patients were on therapeutic anticoagulation and 34 (59%) were on aspirin, while 26 (45%) patients were on an angiotensinconverting-enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB). Myeloma characteristics The cohort included 54 MM and 4 SMM patients (Table 2). The median time from diagnosis to COVID-19 infection was 29.8 months (IQR: 44.2 months). MM patients had a median of 1.5 (IQR: 2) lines of therapy and 9 (17%) patients had more than 4 previous lines of treatment.

Twenty-two (41%) patients had a prior autologous stem cell transplant (ASCT). The median age of patients with and without prior ASCT was 63.5 and 70 years, respectively. Of all patients, 27 (47%) had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 at the time of COVID-19 infection. The most common myeloma subtype was IgG (59%) followed by IgA (19%), with light chain involvement in 33% of cases. High-risk cytogenetics were present in 22 (39%) patients, with 18 (33%) patients having an international staging system (ISS) of 1, while 14 (26%) and 10 (19%) patients had ISS 2 and 3, respectively, at time of MM diagnosis. At time of SARS-CoV-2 infection, 3 SMM and 8 MM patients were not on therapy. Among the remaining patients, 28 (48%) patients were being treated with daratumumab, 32 (55%) patients were on immunomodulatory drugs (IMiDs), 22 (38%) were on a proteasome inhibitor (PI), 5 (9%) were on venetoclax, and 30 (52%) patients were on concomitant corticosteroids.

The disease status at the time of SARS-CoV-2 infection included 15 (26%) patients in complete response (CR) or stringent CR (sCR), 11 (19%), 13 (22%) and 2 (3%) patients who had a very good partial response (VGPR), partial response (PR) and stable disease (SD), respectively, and 9 (16%) who had progressive disease (PD). Response status was not evaluable for 8 (14%) of patients (including 4 SMM patients and 1 newly diagnosed patient).

Biochemical parameters at the last routine clinic visit before presentation with COVID-19 were collected to determine if these steady-state parameters would provide insight into which patients are particularly vulnerable (**Table 2**). Twenty patients (35%) had leukopenia (<4 x 10⁹/L) and 7 (12%) lymphocytopenia (grade 3, <0.5 x 10⁹/L) at their last clinic visit. The monoclonal spike (M-spike) was undetectable in 31 (54%) patients. Median serum IgG level of all patients was 805 mg/dL (IQR: 736 mg/dL) and 37% (21/57) of patients had hypogammaglobulinemia (< 700 mg/dL), while 11% (6/57) of patients had severe (< 400 mg/dL) hypogammaglobulinemia.

Immunoparesis, defined as a reduction in one or more of the uninvolved immunoglobulins below the lower limit of normal²², was present in 89% (51/57) of patients.

Clinical course and biochemical parameters

The most common reported symptoms among all patients were fever (70%), cough (65%), and dyspnea (45%). Thirty-six patients were admitted at a hospital for inpatient care, 23 of which were admitted at our healthcare system and had both clinical and biochemical parameters available, as shown in **Table 3**. The median time between self-reported symptom onset and admission was 3 days. Among the 23 patients, 16 (70%) were febrile, and 11 (48%) were tachycardic with a heart rate >100 beats per minute (bpm) at time of presentation. Ten (43%) patients required immediate oxygen support: 7 needed a nasal cannula or non-rebreather mask, 1 needed high flow oxygen and 2 were immediately intubated and required mechanical ventilation.

During their hospital stay, 22 (95%) patients developed fever, 18 (78%) tachycardia (>100 bpm) and 18 (78%) hypoxemia (SpO2 < 93%). Five (22%) patients never required supplemental oxygen and 10 (40%) needed a nasal cannula or non-rebreather mask at some point during hospitalization. Four (17%) patients were treated with high-flow oxygen, continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BiPAP) machines and five (22%) were eventually intubated. Seven (30%) patients required intensive care unit (ICU) care during their hospitalization. The median length of stay was 22 days. Of the 23 patients admitted to our hospital with COVID-19, seven (30%) died. When we consider the total hospitalized cohort (36 patients, i.e. including patients admitted at other hospitals), the mortality rate was 39% (14 patients). All 14 deaths were due to COVID-19. There were no deaths reported in patients who were not hospitalized among the total cohort.

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

Patients presented with multiple elevated inflammatory markers, including CRP (median: 89 mg/L), ferritin (median: 595 µg/L), IL-6 (median: 82.4 pg/mL), whereas procalcitonin was normal (median: 0.2 ng/mL). Leukocytes were not elevated (median: 4.3x109/L) and the absolute lymphocyte count was low (median 0.6 x 10⁹/L) whereas absolute neutrophil count was within normal range (median 3.6 x 10⁹/L). On initial presentation, lactate dehydrogenase (LDH, median 249.5 U/L), fibrinogen (median 600 mg/dL) and D-dimer (median 1.2 mg/L) were elevated but transaminases were normal (median aspartate aminotransferase (AST) and alanine aminotransferase (ALT): 24 U/L and 20 U/L, respectively). Peak levels for these markers are shown in Table 3 and temporal trends for a subset of patients are illustrated in Supplementary Figure S1. CRP and ferritin peaked early (within the first 10 days of hospitalization) and subsequently demonstrated a downward trend over time, with a slower decline in ferritin levels notable in patients that eventually died. D-dimer level was transiently elevated in some patients but was persistently and progressively elevated in all patients that eventually died. The inflammatory cytokines IL-1β, IL-6, IL-8 and TNF-α, were assessed over the duration of hospitalization at the discretion of the treating physician. Peak levels for IL-6, IL-8 and TNF-α were elevated (median: 128.5 pg/mL, 65.4 pg/mL and 28.7 pg/mL, respectively) and levels for IL-1β were generally low (median: 0.5pg/mL).

We describe COVID-19 management comprehensively for the 23 patients hospitalized at our center and their outcome (**Table 3**). One (4%) patient received remdesivir, 17 (74%) patients received hydroxychloroquine and 17 (74%) patients received azithromycin. Nineteen (82%) patients were treated with other antibiotics, most commonly a beta-lactam antibiotic \pm vancomycin (n = 16) for presumed bacterial superinfection. Six (26%) patients received granulocyte colony stimulating factor (G-CSF) and 18 (78%) patients received therapeutic anticoagulation, 13 of which had not been on full anticoagulation before COVID-19. Patients were treated with a direct oral anticoagulant (DOAC, n = 3), therapeutic doses of enoxaparin (n

= 8) or a heparin drip (n = 2). There were no major bleeding events. Ten (43%) patients were given systemic corticosteroids. One (4%) patient was treated with convalescent plasma. Anti-TNF α , anti-IL-6 and anti-IL-1 therapy was initiated in 1 (4%), 4 (17%) and 2 (9%) patients, respectively. Five patients (22%) were given low dose selinexor, a selective inhibitor of nuclear export, for its presumed activity against virus host protein interaction²³ and to counter amplification of pro-inflammatory signaling²⁴.

Antibody serology and repeat PCR testing

We collected data on antibody testing and follow up PCR testing for patients. As of May 28, 2020, 96% (22/23) of patients have developed antibodies against SARS-CoV-2 at a median time of 32 (range 6-50) days since COVID-19 diagnosis. Titers ranged from 1:160 to 1:2880, with 74% (17/23) exhibiting the most significant titer level of 1:2880, 9% (2/23) with 1:960, 9% (2/23) with 1:320, and 4% (1/23) with 1:160. Antibody titer did not correlate with COVID-19 severity, yet we observed that all 5 MM patients with low titers (< 1:2880) had hypogammaglobulinemia. The one patient who did not develop any antibodies had SMM and was tested 27 days after initial diagnosis. So far, 27 patients have undergone repeat PCR testing; 74% (20/27) are negative and median time to PCR negativity was 43 (range 19-68) days from initial positive PCR. Among the 22 patients with positive antibody titers, 19 patients had repeat PCR swab and 3 remained positive while 16 were negative.

Clinical associations

In a univariate analysis on all patients, we found that the following variables were significantly associated with hospitalization, as shown in **Table 4**: age over 70 (OR 7.74, p = 0.007), male sex (OR 3.70, p = 0.030), diabetes mellitus type 2 (OR 6.18, p = 0.016), high cardiovascular risk profile (OR 3.42, p = 0.032), history of CAD (OR ∞ , p = 0.009), history of CHF (OR ∞ , p = 0.037), use of statins (OR = 12.10, p < 0.001) and use of beta blockers (OR 9.63, p = 0.002).

We also noted significant associations between hospitalization status and grade 3 lymphocytopenia (OR ∞ , p = 0.036) at the last clinic visit prior to COVID-19 infection. Patients who had not achieved complete remission or stringent complete remission were at increased risk of hospitalization (p = 0.013).

Similarly, for hospitalized patients, using a univariate approach, we found statistically significant association between mortality and these variables: non-white race (OR 10.49, p = 0.011), statin use (OR 6.21, p = 0.012), severe hypogammaglobulinemia (OR 7.80, p = 0.027), and higher peak levels of D-dimer (p = 0.004), ferritin (p = 0.007), procalcitonin (p = 0.010), and CRP (p = 0.019). The full list of associations is shown in **Table 4**.

Discussion

Situated in the heart of New York City, our cancer center at Mount Sinai Hospital bore witness to the immense disruption of healthcare caused by COVID-19. During the initial phase of the pandemic, the goal was to keep patients at home following federal and state guidelines of isolation, social distancing, and strict hand hygiene²⁵⁻²⁷. Patients were switched to all oral regimens if possible or had delayed therapy depending on perceived risk of need for therapy to control myeloma versus exposure to SARS-CoV-2. Yet community transmission of SARS-CoV-2 during the pandemic was inevitable.

There were no deaths among myeloma patients with milder symptoms who were managed entirely as outpatients with COVID-19 in this cohort. The mortality rates of the overall cohort (n = 58), MM patients admitted to Mount Sinai Hospital (n = 23), and all admitted MM patients (n = 36) were 24%, 30%, and 39% respectively. These figures are in line with the overall mortality seen in New York, where the estimated mortality among hospitalized patients over 45 years old

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

is 37% as of May 25, 2020^{1,28}. Interestingly the mortality among our cohort of MM patients was lower than the 54.6% seen in a mixed cohort of MM patients treated in Britain²⁹. We acknowledge that the apparent mortality differences between different countries and health systems may be affected by the local epidemiology, hospitalization and resource utilization rates and potential differences in escalation of care. However, in both of these populations, there appeared to be a trend toward increased mortality in patients of non-white/Caucasian background. This has been consistently seen in the United States, where death rates for COVID-19 are several fold higher in patients of Black and Hispanic origins³⁰⁻³².

MM specific disease characteristics and the type of MM treatment were not associated with increased mortality. In contrast, we observed that age and cardiovascular risk factors (diabetes, CAD, CHF) were significantly associated with patient hospitalization for COVID-19. The data from our cohort showed that non-white background. severe 400 mg/dL) hypogammaglobulinemia, and statin use were significantly associated with mortality. This information would indicate that during the post pandemic phase, we do not have to change the management of myeloma patients. However, earlier diagnosis of COVID-19 and prompt intervention especially for the vulnerable population identified above is warranted to reduce the risk of mortality. As we reopen and move forward into a post-COVID-19 era, we will need to remain vigilant, particularly for select patient groups, and await effective COVID-19 treatments while balancing the need to manage patients' myeloma.

We were able to capture the evolution of inflammatory markers for patients who were admitted to the inpatient service and we found a significant association with mortality in patients who had elevated D-dimer, CRP, or ferritin. Many COVID-19 patients treated at our institution also received a rapid panel for cytokine testing as part of a larger study to characterize the inflammatory profile of COVID-19 illness. Among our cohort of hospitalized patients, those who

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

died appeared to exhibit rather elevated pro-inflammatory cytokines, consistent in principle with what was seen in a large COVID-19 cohort analyzed at the Mount Sinai Health System³³. It is possible that a CRS-like syndrome, similar though not identical to one seen in MM patients treated with CAR-T^{14,34} and bispecific antibodies^{35,36}, occurs in a significant portion of MM patients afflicted with COVID-19. Various agents including but not limited to anti-IL-639 monoclonal antibodies and JAK inhibitors⁴⁰ are presently under investigation to address potential components of immune dysregulation in COVID-19. We noted that patients who died from COVID-19 had alarmingly elevated D-dimer levels compared to survivors (median of 18.24 mg/L vs 1.96 mg/L). Emerging research suggests that the overwhelming immune activation during SARS-CoV-2 infection is a potent catalyst for significant arterial and venous thromboembolism leading to strokes and pulmonary emboli^{16,37}, and serum pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6 have been tied to endothelial damage underlying thrombus formation seen in COVID-19³⁸. To counter this possibility, a large majority of patients admitted to our institution in this cohort received therapeutic anticoagulation and none suffered bleeding events. Our data regarding inflammatory markers raises the question if the process driving severe D-dimer elevation in MM patients with COVID-19 is the same or is separate from the CRS-like process seen in many COVID-19 patients.

Data on the persistence of SARS-CoV-2 by PCR and development of specific antibody response to the virus in potentially immunocompromised cancer patients have thus far been lacking. A significant majority of tested patients among this cohort cleared infection by PCR and developed antibodies despite a very high proportion of patients who fit the definition of classical myeloma-associated immunoparesis. Immunoparesis alone was not significantly associated with hospitalization or mortality and importantly did not appear to affect the development of anti-SARS-CoV-2 antibodies. Looking forward, we will need to determine if development of antibodies confers protection against reinfection.

This study has the limitations of single institution, retrospective reporting of a smaller cohort of patients. Serological data were not available for a minority of the patients who were hospitalized at outside institutions. The observations reported here have to be confirmed by a larger series of data collected from multiple institutions and such efforts are underway. Few patients received COVID-19 directed treatment on clinical trials. The role of recently emergency approved antiviral agent remdesivir or convalescent plasma should be explored in the high-risk population with myeloma.

Conclusions

In this study of patients treated for myeloma at the Mount Sinai Hospital, we provide a detailed analysis of a cohort of 58 MM and SMM patients who developed COVID-19. Although several demographic factors and comorbidities increased risk of hospitalization and mortality, myeloma therapy and immunoparesis did not influence outcomes. In fact, survival was comparable to the overall population of New York during the pandemic, and patients generally mounted a significant antibody response to SARS-CoV-2. The data herein supports the need to maintain proactive management of MM patients by balancing their need for therapy with the increased risk of hospitalization and death in a subset of MM patients with COVID-19.

Abbreviations

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

ACE: angiotensin-converting-enzyme; ALT: alanine aminotransferase; ARB: angiotensin receptor blocker; ASCT: autologous stem cell transplant; AST: aspartate aminotransferase; BiPAP: bi-level positive airway pressure; BMI: body mass index; bpm: beats per minute; CAD: coronary artery disease; CAR: chimeric antigen receptor; CHF: congestive heart failure; CKD: chronic kidney disease; COPD: chronic obstructive lung disease; COVID-19: coronavirus disease 2019; CPAP: continuous positive airway pressure; CR: complete response; CRS: cytokine release syndrome; CRP: C-reactive protein; DOAC: direct oral anticoagulant; ECOG: Eastern Cooperative Oncology Group; eGFR: estimated glomerular filtration rate; ELISA: enzyme-linked immunosorbent assay; G-CSF: granulocyte colony stimulating factor; HIPAA: Health Insurance Portability and Accountability Act; IMWG: International Myeloma Working Group; ICU: intensive care unit; IL: interleukin; IMiD: immunomodulatory drug; IRB: institutional review board; IQR: interquartile range; ISS: international staging system; LDH: lactate dehydrogenase; MM: Multiple myeloma; OR: odd's ratio; PCR: polymerase chain reaction; PD: progressive disease; PI: proteasome inhibitor; PR: partial response;

SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2; sCR: stringent

complete response; SD: stable disease; SMM: smoldering multiple myeloma; TNF-α:

tumor necrosis factor-α; VGPR: very good partial response.

Author Contributions

- Conceptualization, BW, OVO, THM, SJ, SP, and DM; Methodology, OVO; Investigation, BW,
- OVO, THM, DV and SG; Writing Original Draft, BW, OVO, THM; Writing Review & Editing,
- 432 all authors; Funding Acquisition, SJ.; Resources, MM, SJ, SP and DM; Supervision, MM, SJ, SP
- 433 and DM.

Conflict of Interest:

1R01CA244899-01A1.

A.C.: Advisory board and consulting fees from Amgen, Antegene, Celgene, Janssen, Karyopharm, Millennium/Takeda, Novartis Pharmaceuticals, Oncopeptides, Sanofi; research funding from Amgen, Celgene, Janssen, Millennium/Takeda, Novartis Pharmaceuticals, Pharmacyclics. S. J.: Advisory board and consulting fees from Celgene, Bristol-Myers Squibb, Janssen Pharmaceuticals and Merck. H. J. C: Employed by the Multiple Myeloma Research Foundation, advisory board and consulting fees from Genetech, Celgene, Bristol Myers Squibb, GlaxoSmithKline and received research funding from Takeda, Celgene, and Genetech. D. M.: Advisory board and consulting fees from Janssen, Celgene, Bristol Myers Squibb, Takeda, Legend, GlaxoSmithKline,Kinevant, and Foundation Medicine. B.W.: Consulting fees from Sanofi Genzyme. J. R.: Speaking fees from Celgene and Janssen, advisory board and consulting fees from Celgene, Janssen, Bristol Myers Squibb, Oncopeptides, Adaptive Biotechnologies, X4 Pharmaceuticals, Karyopharm, and Antegene. S. P.: Consulting fees from Foundation Medicine, research funding from Celgene and Karyopharm. Supported by

Acknowledgements

We would like to acknowledge all the staff and families for the selfless efforts in caring for patients who developed COVID-19, and the strength and courage of all patients affected by the pandemic.

Funding

There is no outside funding declared for this study.

References

460

- 461 1. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and
- Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020.
- 463 2. https://covid19tracker.health.ny.gov/
- 464 3. Robilotti EV, Babady NE, Mead PA, et al. Determinants of Severity in Cancer Patients with
- 465 COVID-19 Illness. medRxiv 2020:2020.05.04.20086322.
- 466 4. Dai M, Liu D, Liu M, et al. Patients with Cancer Appear More Vulnerable to SARS-COV-2: A
- 467 Multicenter Study during the COVID-19 Outbreak. Cancer Discov 2020.
- Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis
- 469 in China. Lancet Oncol 2020;21:335-7.
- 470 6. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary
- 471 Care Hospital in Wuhan, China. JAMA Oncology 2020.
- 472 7. Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a
- 473 retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020.
- 474 8. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111:2962-72.
- 475 9. Lee SJ, Borrello I. Role of the Immune Response in Disease Progression and Therapy in Multiple
- 476 Myeloma. Cancer Treat Res 2016;169:207-25.
- 477 10. Kumar SK, Anderson KC. Immune Therapies in Multiple Myeloma. Clinical Cancer Research
- 478 2016;22:5453-60.
- 479 11. Ingraham NE, Lotfi-Emran S, Thielen BK, et al. Immunomodulation in COVID-19. The Lancet
- 480 Respiratory Medicine.
- 481 12. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and
- 482 immunosuppression. Lancet 2020.
- 483 13. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for
- 484 monocytes and macrophages. Nature Reviews Immunology 2020.
- 485 14. Liu D, Zhao J. Cytokine release syndrome: grading, modeling, and new therapy. Journal of
- 486 Hematology & Oncology 2018;11:121.
- 487 15. Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release
- 488 Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant
- 489 2019;25:625-38.
- 490 16. Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q. The cytokine release syndrome (CRS) of severe
- 491 COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the
- 492 mortality. International Journal of Antimicrobial Agents 2020:105954.
- 493 17. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider
- 494 cytokine storm syndromes and immunosuppression. Lancet (London, England) 2020;395:1033-4.
- 495 18. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in
- 496 Wuhan, China. Lancet (London, England) 2020;395:497-506.
- 497 19. Gong J, Dong H, Xia SQ, et al. Correlation Analysis Between Disease Severity and Inflammation-
- related Parameters in Patients with COVID-19 Pneumonia. medRxiv 2020:2020.02.25.20025643.
- 499 20. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated
- criteria for the diagnosis of multiple myeloma. The Lancet Oncology 2014;15:e538-48.
- 501 21. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria
- for response and minimal residual disease assessment in multiple myeloma. The Lancet Oncology
- 503 2016;17:e328-e46.
- 504 22. Sørrig R, Klausen TW, Salomo M, et al. Smoldering multiple myeloma risk factors for
- progression: a Danish population-based cohort study. European Journal of Haematology 2016;97:303-9.

- 506 23. Widman DG, Gornisiewicz S, Shacham S, Tamir S. In vitro toxicity and efficacy of verdinexor, an
- 507 exportin 1 inhibitor, on opportunistic viruses affecting immunocompromised individuals. PloS one
- 508 2018;13:e0200043.
- 509 24. Wu M, Gui H, Feng Z, et al. KPT-330, a potent and selective CRM1 inhibitor, exhibits anti-
- 510 inflammation effects and protection against sepsis. Biochemical and biophysical research
- 511 communications 2018;503:1773-9.
- 512 25. Al Saleh AS, Sher T, Gertz MA. Multiple Myeloma in the Time of COVID-19. Acta haematologica
- 513 2020:1-7.
- 514 26. Society IM. Recommendations for the Management of Myeloma Patients During the COVID-19
- 515 Pandemic. 2020.
- 516 27. Malard F, Mohty M. Management of patients with multiple myeloma during the COVID-19
- 517 pandemic. The Lancet Haematology 2020.
- 518 28. COVID-19: Data. 2020. at https://www1.nyc.gov/site/doh/covid/covid-19-data.page.)
- 519 29. Cook G, Ashcroft AJ, Pratt G, et al. Real-world assessment of the clinical impact of symptomatic
- 520 infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with
- Multiple Myeloma receiving systemic anti-cancer therapy. British Journal of Haematology; n/a.
- 522 30. Gross CP, Essien UR, Pasha S, Gross JR, Wang S-y, Nunez-Smith M. Racial and Ethnic Disparities
- in Population Level Covid-19 Mortality. medRxiv 2020:2020.05.07.20094250.
- 524 31. Henning-Smith C, Tuttle M, Kozhimannil KB. Unequal Distribution of COVID-19 Risk among Rural
- 525 Residents by Race and Ethnicity. The Journal of rural health: official journal of the American Rural
- Health Association and the National Rural Health Care Association 2020.
- 527 32. Howard G, Safford MM, Moy CS, et al. Racial Differences in the Incidence of Cardiovascular Risk
- Factors in Older Black and White Adults. Journal of the American Geriatrics Society 2017;65:83-90.
- 529 33. Diane Marie Del Valle M, Seunghee Kim-Schulze PD, Hsin-Hui Huang PD, et al. An inflammatory
- 530 cytokine signature helps predict COVID-19 severity and death. MEDRXIV 2020;115758.
- 34. Jatiani SS, Aleman A, Madduri D, et al. Myeloma CAR-T CRS Management with IL-1R Antagonist
- Anakinra. Clinical Lymphoma Myeloma and Leukemia 2020.
- 533 35. Dai H, Wu Z, Jia H, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of
- 534 adults with relapsed or refractory B cell acute lymphoblastic leukemia. Journal of Hematology &
- 535 Oncology 2020;13:30.
- 536 36. Costa LJ WS, Bermúdez A. First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell
- engager (TCE) CC-93269 in patients (pts) with relapsed/refractory multiple myeloma (RRMM): interim
- results of a phase 1 multicenter trial. Abstract #143. American Society of Hematology. Orlando, FL: ASH
- 539 Annual Meeting Proceedings; 2019.
- 540 37. Tseng C-TK, Perrone LA, Zhu H, Makino S, Peters CJ. Severe Acute Respiratory Syndrome and the
- 541 Innate Immune Responses: Modulation of Effector Cell Function without Productive Infection. The
- 542 Journal of Immunology 2005;174:7977-85.
- 543 38. Bryce C, Grimes Z, Pujadas E, et al. Pathophysiology of SARS-CoV-2: targeting of endothelial cells
- renders a complex disease with thrombotic microangiopathy and aberrant immune response. The
- Mount Sinai COVID-19 autopsy experience. medRxiv 2020:2020.05.18.20099960.
- 546 39. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab.
- Proceedings of the National Academy of Sciences 2020;117:10970-5.
- 548 40. Cao Y, Wei J, Zou L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-
- 549 19): A multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology
- 550 2020.

Tables

552

553

Table 1: Demographics and baseline characteristics of patients

	All patients		adı	ents not mitted ospital		Hospitalized, discharged alive		Hospitalized, deceased	
	I	n = 58	n	= 22	ı	ı = 22	n	= 14	
Demographics									
Age (years)	67	[12.5]	64	[11.5]	71	[18.5]	68	[8]	
Sex (male)	52%	(30)	32%	(7)	68%	(15)	57%	(8)	
Race (non-white)	63%	(36/57)	55%	(12)	55%	(12/22)	92%	(12)	
BMI (kg/m2)	27.6	[7.9]	26.1	[5.3]	28.2	[10.2]	29.5	[9.9]	
Obesity (BMI > 30 kg/m2)	37%	(21/57)	27%	(6)	38%	(8/21)	50%	(7)	
Comorbidities									
High cardiovascular risk profile (≥2 of hypertension, hyperlipidemia, diabetes)	55%	(32)	36%	(8)	64%	(14)	71%	(10)	
Hypertension	64%	(37)	59%	(13)	59%	(13)	79%	(11)	
Hyperlipidemia	62%	(36)	50%	(11)	59%	(13)	86%	(12)	
Diabetes	28%	(16)	9%	(2)	45%	(10)	29%	(4)	
Previous atherosclerotic complications (CAD and/or CVA)	22%	(13)	0%	(0)	36%	(8)	36%	(5)	
Congestive heart failure	12%	(7)	0%	(0)	14%	(3)	29%	(4)	
Current or former smoker	37%	(21/57)	27%	(6)	38%	(8/21)	50%	(7)	
Lung disease (COPD, emphysema, asthma, bronchiectasis)	21%	(12)	18%	(4)	27%	(6)	14%	(2)	
Chronic kidney disease (eGFR < 60 mL/min)	24%	(14)	23%	(5)	27%	(6)	21%	(3)	
History of other malignancy	9%	(5)	5%	(1)	5%	(1)	21%	(3)	
Number of comorbidities	2	[3]	1	[1.75]	3	[3]	3.5	[1.75]	
Concomitant medication									
Anticoagulation	21%	(12)	9%	(2)	27%	(6)	29%	(4)	
Aspirin	59%	(34)	59%	(13)	59%	(13)	57%	(8)	
Statin	47%	(27)	14%	(3)	59%	(13)	79%	(11)	
ACE inhibitor or angiotensin II receptor blocker	45%	(26)	36%	(8)	41%	(9)	64%	(9)	
Beta blocker	34%	(20)	9%	(2)	50%	(11)	50%	(7)	
Metformin	16%	(9)	5%	(1)	32%	(7)	7%	(1)	
Non-steroidal anti-inflammatory drug	5%	(3)	5%	(1)	5%	(1)	7%	(1)	
Oral corticosteroids	53%	(31)	45%	(10)	50%	(11)	71%	(10)	
COVID-19 confirmed by PCR at MSH	71%	(41)	59%	(13)	86%	(19)	64%	(9)	

Note: values are presented as percentage (n) or median [interquartile range].

Abbreviations: BMI, body mass index; CAD, coronary artery disease; CVA, cerebrovascular accident; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; ACE, angiotensin converting enzyme; NSAID, non-steroidal anti-inflammatory drug; MSH, Mount Sinai Hospital

Table 2: Myeloma disease characteristics of patients

556

	All patients		adm	Patients not admitted to hospital		Hospitalized, discharged alive		Hospitalized, deceased	
	I	n = 58		= 22	n	= 22	n	= 14	
Disease characteristics									
SMM	7%	(4)	9%	(2)	5%	(1)	7%	(1)	
SMM/MM subtype									
lgD	2%	(1)	5%	(1)	0%	(0)	0%	(0)	
lgG	59%	(34)	59%	(13)	64%	(14)	50%	(7)	
IgA	19%	(11)	23%	(5)	14%	(3)	21%	(3)	
Light chain disease	33%	(19)	23%	(5)	41%	(9)	36%	(5)	
Extramedullary disease history	31%	(18)	36%	(8)	32%	(7)	21%	(3)	
ISS at diagnosis									
1	33%	(18/54)	45%	(9/20)	43%	(9/21)	0%	(0/13)	
2	26%	(14/54)	25%	(5/20)	33%	(7/21)	15%	(2/13)	
3	19%	(10/54)	20%	(4/20)	14%	(3/21)	23%	(3/13)	
not known	22%	(12/54)	10%	(2/20)	10%	(2/21)	62%	(8/13)	
High risk cytogenetics	39%	(22/56)	33%	(7/21)	41%	(9)	46%	(6/13)	
Time since MM diagnosis (months)	29.8	[44.2]	44.8	[38.7]	27.2	[55.8]	28.6	[23.6]	
History of ASCT	41%	(22/54)	60%	(12/20)	24%	(5/21)	38%	(5/13)	
Time since ASCT (days)	985	[1590]	985	[744]	2148	[2206]	460	[1734]	
ASCT within last year	9%	(5/54)	15%	(3/20)	0%	(0/21)	15%	(2/13)	
Lines of therapy (n)	1.5	[2]	2	[2]	2	[3]	1	[1]	
More than 4 lines of treatment	17%	(9/54)	20%	(4/20)	19%	(4/21)	8%	(1/13)	
ECOG 0	47%	(27)	64%	(14)	41%	(9)	29%	(4)	
Current response status*	4770	(27)	0470	(17)	4170	(5)	2370	(+)	
sCR or CR	26%	(15)	45%	(10)	14%	(3)	14%	(2)	
VGPR	19%	(11)	18%	(4)	14%	(3)	29%	(4)	
PR	22%	(11)	18%	(4)	23%	(5)	29%		
SD	3%		5%				0%	(4)	
		(2)		(1)	5%	(1)		(0)	
PD Net probable	16%	(9)	5%	(1)	23%	(5)	21%	(3)	
Not evaluable	14%	(8)	9%	(2)	23%	(5)	7%	(1)	
Current MM treatment regimen									
Contains CD38 mAb	48%	(28)	50%	(11)	50%	(11)	43%	(6)	
Contains IMID	55%	(32)	55%	(12)	59%	(13)	50%	(7)	
Contains proteasome inhibitor	38%	(22)	27%	(6)	41%	(9)	50%	(7)	
Contains corticosteroids	52%	(30)	45%	(10)	50%	(11)	64%	(9)	
Contains venetodax	9%	(5)	14%	(3)	9%	(2)	0%	(0)	
No active treatment	19%	(11)	18%	(4)	18%	(4)	21%	(3)	
Biochemical parameters at last clinic visit before COVID-19 episode									
Leukocyte count (x10e9/L)	4.6	[2.1]	4.1	[2.1]	5.2	[2.4]	4.7	[1.5]	
Leukocytopenia (< 4 x 10e9/L)	35%	(20/57)	41%	(9)	33%	(7/21)	29%	(4)	
Absolute neutrophil count (x10e9/L)	2.6	[2.2]	2.4	[1]	3.4	[3]	2.4	[1.4]	
Neutropenia (< 2 x10e9/L)	26%	(15/57)	32%	(7)	29%	(6/21)	14%	(2)	
Absolute lymphocyte count (x10e9/L)	1	[0.8]	1.1	[1.2]	0.8	[0.9]	1.2	[0.5]	
Lymphocytopenia (< 0.5 x 10e9/L)	12%	 (7/57)	0%	(0)	33%	(7/21)	0%	(0)	
Serum free light chain ratio (involved/uninvolved)	2.5	[11.9]	1.6	[3.3]	7.7	[45.5]	1.8	[5.2]	
M spike (g/dL)	0	[0.6]	0	[0.2]	0.3	[1.2]	0.1	[0.4]	
IgG (mg/dL)	805	[736]	1074.5	[683.8]	764	[1121]	727	[496.8]	
Hypogammaglobulinemia (IgG < 700 mg/dL)	37%	(21/57)	32%	(7)	38%	(8/21)	43%	(6)	

Severe hypogammaglobulinemia (IgG < 400 mg/dL)	11%	(6/57)	0%	(0)	10%	(2/21)	29%	(4)
lmm unopares is	89%	(51/57)	82%	(18)	95%	(20/21)	93%	(13)

 $\textbf{Note} \colon \text{values are presented as percentage (n) or median [interquartile range]}.$

557

558

Abbreviations: SMM, smoldering multiple myeloma; Ig, immunoglobulin; ISS, international staging system; MM, multiple myeloma; ASCT, autologous stem cell transplant; ECOG. Eastern Cooperative Oncology Group; sCR, stringent complete response; CR, complete response; VGPR, very good partial response; SD, stable disease; PD, progressive disease; mAb, monoclonal antibody; IMiD, immunomodulatory agent; *according to IMWG criteria

Table 3: Clinical parameters, treatments and outcomes of patients hospitalized due to COVID-19 at Mount Sinai Hospital

559

560

561

Subset of patients treated at Mount Sinai hospital for which full clinical data was available	-	italized nts total	1	italized nts alive	Hospitalized patients deceased		
	n	= 23	n = 16		n = 7		
Clinical presentation							
Fever	70%	(16)	69%	(11)	71%	(5)	
Systolic BP < 90 mmHg	9%	(2)	0%	(0)	29%	(2)	
MAP < 65 mmHg	9%	(2)	0%	(0)	29%	(2)	
Heartrate > 100 bpm	48%	(11)	56%	(9)	29%	(2)	
RR > 20/min	26%	(6)	19%	(3)	43%	(3)	
Oxygen requirement at presentation							
None	57%	(13)	69%	(11)	29%	(2)	
Nasal cannula or NRB mask	30%	(7)	25%	(4)	43%	(3)	
High-flow oxygen, CPAP or BiPAP	4%	(1)	0%	(0)	14%	(1)	
Mechanical ventilation	9%	(2)	6%	(1)	14%	(1)	
Treatment initiated							
Remdesivir	4%	(1)	6%	(1)	0%	(0)	
Hydroxychloroquine	74%	(17)	69%	(11)	86%	(6)	
Azithromycin	74%	(17)	75%	(12)	71%	(5)	
Other antibiotics	83%	(19)	81%	(13)	86%	(6)	
G-CSF	26%	(6)	38%	(6)	0%	(0)	
Therapeutic anticoagulation	78%	(18)	69%	(11)	100%	(7)	
Systemic corticosteroids	43%	(10)	31%	(5)	71%	(5)	
Anti-TNF	4%	(1)	0%	(0)	14%	(1)	
Anti-IL-1	9%	(2)	0%	(0)	29%	(2)	
Anti-IL-6	17%	(4)	13%	(2)	29%	(2)	
Selinexor	22%	(5)	25%	(4)	14%	(1)	
Convalescent plasma	4%	(1)	6%	(1)	0%	(0)	
Complications							
Highest level of oxygen requirement							
None	26%	(6)	31%	(5)	14%	(1)	
Nasal cannula or NRB mask	39%	(9)	56%	(9)	0%	(0)	
High-flow oxygen, CPAP or BiPAP	13%	(3)	6%	(1)	29%	(2)	
Mechanical ventilation	22%	(5)	6%	(1)	57%	(4)	
ICU	30%	(7)	6%	(1)	86%	(6)	
Acute kidney injury	52%	(12)	38%	(6)	86%	(6)	
Shock	30%	(7)	0%	(0)	100%	(7)	
Sepsis or HAP/VAP	9%	(2)	6%	(1)	14%	(1)	
C. difficile infection	4%	(1)	6%	(1)	0%	(0)	
Cardiac complication	30%	(7)	19%	(3)	57%	(4)	
Worst biochemical parameters							
CRP	151.5	[178.1]	144.9	[107.7]	294.1	[132.9]	
Total leukocyte count (x10e9/L) (lowest)	3.3	[2.6]	2.9	[2.4]	4.3	[8.4]	
Absolute lymphocyte count (x10e9/L) (lowest)	0.3	[0.4]	0.4	[0.5]	0.2	[0.2]	
Creatinine (mg/dL)	1.6	[2.4]	1.1	[1.4]	2.7	[2]	
Procalcitonin (ng/mL)	0.8	[2.1]	0.5	[0.8]	2.7	[9.9]	

Ferritin (µg/L)	2537	[2578]	1282	[2170.5]	3409	[2018]
Fibrinogen (mg/dL)	667	[167]	646	[209.5]	673.5	[43.8]
D-dimer (mg/L)	2.5	[14.3]	2	[2.6]	20	[7.6]
LDH (U/L)	531.5	[515.8]	478	[329]	739	[344]
ALT (U/L)	61	[58.5]	43.5	[52.8]	79	[32]
AST (U/L)	78	[62.5]	49.5	[54.3]	101	[51.5]
IL-1β (pg/mL)	0.5	[0.9]	0.5	[0.8]	0.5	[0.9]
IL-6 (pg/mL)	128.5	[211.6]	119.3	[102.4]	296.8	[821.2]
IL-8 (pg/mL)	65.4	[62.3]	46.6	[67.6]	137	[89.6]
TNF-alfa (pg/mL)	28.7	[11]	29.4	[8.4]	21.3	[15.2]

Note: values are presented as percentage (n) or median [interquartile range].

562

563

Abbreviations: BP, blood pressure; MAP, mean arterial pressure; SpO2, oxygen saturation; RR, respiratory rate; NRB, non-rebreather; CPAP, continuous positive airway pressure; BiPAP, bi-level positive airway pressure; G-CSF, granulocyte colony stimulating factor; TNF, tumor necrosis factor; IL, interleukin; ICU, intensive care unit; HAP, hos pital-acquired pneumonia; VAP, ventilator-associated pneumonia; CRP, C-reactive protein; LDH, lactate dehydrogenase; ALT, alanine aminotransferase; AST, aspartate aminotransferase

Table 4: Univariate associations of selected variables with risk of hospitalization and mortality

564

565

	Hospitalized vs non-hospitalized n = 58		Mortality (dead vs alive)	n = 58
	OR [95% CI] or median NH/H	p value	OR [95% CI] or median dead/alive	<i>p</i> value
Demographics				
Age (> 70 years)	7.74 [1.51 - 78.12]	0.007	1.32 [0.29 - 5.47]	0.744
Sex (male)	3.7 [1.08 - 13.81]	0.030	1.33 [0.34 - 5.48]	0.762
Race (non-white)	1.87 [0.55 - 6.51]	0.275	10.49 [1.35 - 481.76]	0.011
Obesity (BMI ≥ 30 kg/m2)	1.98 [0.56 - 7.72]	0.272	2.04 [0.5 - 8.4]	0.340
Comorbidities				
High cardiovascular risk profile (≥2 of hypertension, hyperlipidemia, diabetes)	3.42 [1.01 - 12.4]	0.032	2.46 [0.59 - 12.43]	0.221
Hypertension	1.38 [0.4 - 4.73]	0.585	2.5 [0.55 - 15.93]	0.220
, . Hyperlipidemia	2.24 [0.66 - 7.81]	0.170	4.88 [0.92 - 49.98]	0.057
Diabetes	6.18 [1.19 - 62.84]	0.016	1.07 [0.2 - 4.67]	1.000
Coronary artery disease	Inf [1.64 - Inf]	0.009	2.49 [0.43 - 13.07]	0.233
Stroke	∞ [0.58 - ∞]	0.145	2.24 [0.17 - 22.05]	0.585
Congestive heart failure	∞ [0.96 - ∞]	0.037	5.26 [0.76 - 41.93]	0.051
Current or former smoker	1.98 [0.56 - 7.72]	0.272	2.04 [0.5 - 8.4]	0.340
Lung disease (COPD, emphysema, asthma, bronchiectasis)	1.28 [0.29 - 6.69]	1.000	0.57 [0.05 - 3.3]	0.711
Chronic kidney disease (eGFR < 60 mL/min)	1.13 [0.28 - 5.06]	1.000	0.82 [0.12 - 3.97]	1.000
History of other malignancy	2.59 [0.23 - 135.24]	0.640	5.51 [0.56 - 73.43]	0.085
Number of comorbidities	1/3	0.011	2/3.5	0.055
Concomitant medications				
Anticoagulation	3.77 [0.69 - 39.19]	0.108	1.78 [0.32 - 8.51]	0.457
ACE inhibitor or angiotensin II receptor blocker	1.73 [0.52 - 6.06]	0.416	2.81 [0.7 - 12.6]	0.126
Beta blocker	9.63 [1.89 - 97.14]	0.002	2.35 [0.58 - 9.72]	0.203
Metformin	5.85 [0.69 - 278.29]	0.133	0.35 [0.01 - 3.08]	0.431
Statin	12.06 [2.78 - 76.13]	<0.001	6.21 [1.37 - 39.77]	0.012
Aspirin	0.97 [0.28 - 3.23]	1.000	0.92 [0.23 - 3.83]	1.000
NSAID	1.23 [0.06 - 76.27]	1.000	1.6 [0.03 - 33.14]	1.000
Oral corticosteroids	1.66 [0.51 - 5.61]	0.420	2.69 [0.65 - 13.59]	0.139
Disease characteristics				
Light chain disease	2.09 [0.44 - 13.55]	0.342	1.19 [0.26 - 4.88]	1.000
High risk cytogenetics	1.49 [0.43 - 5.52]	0.577	1.44 [0.33 - 6.03]	0.747
Current response status				
sCR or CR	0.2 [0.04 - 0.8]	0.013	0.4 [0.04 - 2.23]	0.317
Current MM treatment regimen				
Contains CD38 mAb	0.9 [0.27 - 2.95]	1.000	0.75 [0.18 - 2.96]	0.762
Contains IMiD	1.04 [0.31 - 3.43]	1.000	0.76 [0.19 - 3.04]	0.761
Contains proteasome inhibitor	2.11 [0.6 - 8.17]	0.267	1.91 [0.47 - 7.78]	0.350
Contains corticosteroids	1.49 [0.45 - 4.99]	0.589	1.95 [0.49 - 8.67]	0.363
Contains venetodax	0.38 [0.03 - 3.62]	0.357	0 [0 - 3.45]	0.322
No active treatment	1.08 [0.23 - 5.79]	1.000	1.22 [0.18 - 6.34]	1.000

Biochemical parameters at last clinic visit before COVID-19 episode

·				
Leukocytopenia (< 4 x 10e9/L)	0.67 [0.19 - 2.34]	0.571	0.68 [0.13 - 2.88]	0.749
Lymphocytopenia (< 0.5 x 10e9/L)	∞ [0.99 - ∞]	0.036	0 [0 - 2.07]	0.176
Neutropenia (< 2 x10e9/L)	0.64 [0.16 - 2.52]	0.542	0.39 [0.04 - 2.16]	0.312
lgG level (mg/dL)	1074.5 / 738	0.297	869 / 718	0.074
Hypogammaglobulinemia (lgG < 700 mg/dL)	1.42 [0.41 - 5.24]	0.584	1.39 [0.33 - 5.61]	0.751
Severe hypogammaglobulinemia (lgG < 400 mg/d	IL) ∞ [0.79 - ∞]	0.072	7.80 [0.97 - 97.75]	0.027
Immunoparesis	3.58 [0.46 - 43.2]	0.192	1.70 [0.17 - 87.01]	1.000
Peak biochemical parameters during hospitalization			ly to the subset of patients at Sinai Hospital	n = 23
CRP (mg/L)	=	=	144.8 / 289.4	0.019
Total leukocyte count (x10e9/L) (lowest)	-	-	2.9 / 4.2	0.444
Absolute lymphocyte count (x10e9/L) (lowest)	=	-	0.4 / 0.2	0.319
Creatinine (mg/dL)	=	=	1.1 / 2.5	0.052
Procalcitonin (ng/mL)	=	-	0.5 / 2.3	0.010
Ferritin (μg/L)	=	-	1282 / 3474	0.007
Fibrinogen (mg/dL)	=	-	646 / 667	0.888
D-dimer (mg/L)	=	-	2 / 18.2	0.004
LDH (U/L)	=	-	478 / 830	0.065
ALT (U/L)	=	-	43.5 / 76.5	0.244
AST (U/L)	=	-	49.5 / 100	0.054
IL-1b (pg/mL)	=	=	0.5 / 0.5	1.000
IL-6 (pg/mL)	=	=	119.2 / 296.8	0.117
IL-8 (pg/mL)	=	-	46.6 / 137	0.104

Note: values are presented as OR [95% confidence interval] or median of group 1/median of group 2; p values according to Wilcoxon test for continuous variables and Fisher's exact test for categorical variables

29.4 / 21.3

0.574

Abbreviations: OR, odds ratio; CI, confidence interval; NH, not hospitalized; H, hospitalized; BMI, body mass index; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; ACE, a ngiotensin converting enzyme; NSAID, non-steroidal anti-inflammatory drug; ASCT, autologous stem cell transplant; Ig, immunoglobulin; CRP, C-reactive protein; ALT, alanine aminotransferase; AST, as partate aminotransferase; IL, interleukin; TNF, tumor necrosis factor

TNF-alfa (pg/mL)

Supplementary Figures

Figure S1: Evolution of selected inflammatory biomarkers in a subset of patients (n = 12) hospitalized at the Mount Sinai Hospital for which the data was available. Different measurements from the same patient are connected. A linear regression line is plotted for the subgroup of patients that survived (blue, n = 8) and died (red, n = 4), respectively.

